Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicent...

por Inoue, Kenichi, Ninomiya, Jun, Saito, Tsuyoshi, Kimizuka, Kei, Kurosumi, Masafumi
Publicado 2018

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm...

por Inoue, Kenichi, Ninomiya, Jun, Saito, Tsuyoshi, Okubo, Katsuhiko, Nakakuma, Takashi, Yamada, Hirofumi, Kimizuka, Kei, Higuchi, Tohru
Publicado 2019

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance

por Inoue, Kenichi, Saito, Tsuyoshi, Okubo, Katsuhiko, Kimizuka, Kei, Yamada, Hirofumi, Sakurai, Takashi, Ishizuna, Kazuo, Hata, Satoshi, Kai, Toshihiro, Kurosumi, Masafumi
Publicado 2016

TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study

por Inoue, Kenichi, Nagai, Shigenori E., Saito, Tsuyoshi, Sakurai, Takashi, Kimizuka, Kei, Yamada, Hirofumi, Kuroda, Toru, Hata, Satoshi, Yamazaki, Yasuo, Kojima, Masato, Futsuhara, Kazushige
Publicado 2019